QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
NIO   27.86 (-0.36%)
BAC   24.05 (-0.37%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
NIO   27.86 (-0.36%)
BAC   24.05 (-0.37%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
NIO   27.86 (-0.36%)
BAC   24.05 (-0.37%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
NIO   27.86 (-0.36%)
BAC   24.05 (-0.37%)
Log in
NASDAQ:RLAY

Relay Therapeutics Stock Forecast, Price & News

$38.28
-0.71 (-1.82 %)
(As of 10/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$37.76
Now: $38.28
$40.02
50-Day Range
$35.15
MA: $39.86
$45.15
52-Week Range
$32.56
Now: $38.28
$49.89
Volume233,465 shs
Average Volume413,238 shs
Market Capitalization$3.44 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.66 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RLAY
CUSIPN/A
CIKN/A
Phone617-370-8837
Employees122

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$3.44 billion
Next Earnings Date11/26/2020 (Estimated)
OptionableNot Optionable
$38.28
-0.71 (-1.82 %)
(As of 10/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RLAY News and Ratings via Email

Sign-up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Relay Therapeutics (NASDAQ:RLAY) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Relay Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Relay Therapeutics
.

When is Relay Therapeutics' next earnings date?

Relay Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 26th 2020.
View our earnings forecast for Relay Therapeutics
.

How were Relay Therapeutics' earnings last quarter?

Relay Therapeutics (NASDAQ:RLAY) announced its earnings results on Thursday, August, 27th. The company reported ($6.06) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.38) by $5.68.
View Relay Therapeutics' earnings history
.

Who are some of Relay Therapeutics' key competitors?

What other stocks do shareholders of Relay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND), CureVac B.V. (CVAC), Quidel (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG), DraftKings (DKNG), eHealth (EHTH), GoHealth (GOCO) and Intel (INTC).

Who are Relay Therapeutics' key executives?

Relay Therapeutics' management team includes the following people:
  • Mr. Alexis A. Borisy, Co-Founder & Independent Exec. Chairman (Age 48, Pay $17.5k)
  • Dr. Sanjiv K. Patel, CEO, Pres & Director (Age 46, Pay $938.92k)
  • Dr. Mark Murcko, Co-Founder & Director (Age 60, Pay $235k)
  • Mr. Brian R. Adams, Gen. Counsel & Sec. (Age 46, Pay $454.17k)
  • Dr. Donald A. Bergstrom, Exec. VP and Head of R&D (Age 48, Pay $585.86k)

When did Relay Therapeutics IPO?

(RLAY) raised $250 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 14,700,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO.

What is Relay Therapeutics' stock symbol?

Relay Therapeutics trades on the NASDAQ under the ticker symbol "RLAY."

When does Relay Therapeutics' lock-up period expire?

Relay Therapeutics' lock-up period expires on Tuesday, January 12th. Relay Therapeutics had issued 20,000,000 shares in its IPO on July 16th. The total size of the offering was $400,000,000 based on an initial share price of $20.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

How do I buy shares of Relay Therapeutics?

Shares of RLAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Relay Therapeutics' stock price today?

One share of RLAY stock can currently be purchased for approximately $38.28.

How big of a company is Relay Therapeutics?

Relay Therapeutics has a market capitalization of $3.44 billion. Relay Therapeutics employs 122 workers across the globe.

What is Relay Therapeutics' official website?

The official website for Relay Therapeutics is www.relaytx.com.

How can I contact Relay Therapeutics?

Relay Therapeutics' mailing address is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-370-8837 or via email at [email protected]

This page was last updated on 10/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.